Faculty Profiles - IMAI Norihiro

Papers - IMAI Norihiro

Division display 81 - 100 of about 112 ／ All the affair displays >>

Hepatology Highlights.

Shah PA, Lau DTY, Russo NW, Brown RS Jr, Maiers JL, Schwartz RE, Imai N, Krisko TI, Navarro-Corcuera A, Jalan-Sakrikar N, Pisa JF, Jesudian AB, Tafesh ZH, Fortune BE, Kostallari E

Hepatology (Baltimore, Md.) Vol. 71 ( 1 ) page： 1 - 3 2020.1

Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD.

Imai N, Cohen DE

Hepatology (Baltimore, Md.) Vol. 68 ( 6 ) page： 2062 - 2065 2018.12

Hepatocyte-specific depletion of ubiquitin regulatory X domain containing protein 8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model

Imai Norihiro, Suzuki Michitaka, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Ishikawa Tetsuya, Goto Hidemi, Fujimoto Toyoshi

HISTOCHEMISTRY AND CELL BIOLOGY Vol. 148 ( 3 ) page： 219 - 227 2017.9

Hepatocyte-Specific Depletion of UBXD8 Induces Periportal Steatosis in Mice Fed a High-Fat Diet

Imai Norihiro, Suzuki Michitaka, Hayashi Kazuhiko, Ishigami Masatoshi, Hirooka Yoshiki, Abe Takaya, Shioi Go, Goto Hidemi, Fujimoto Toyoshi

PLOS ONE Vol. 10 ( 5 ) page： e0127114 2015.5

Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.

Imai N, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Hirooka Y, Goto H

World journal of hepatology Vol. 6 ( 12 ) page： 844 - 50 2014.12

当院におけるHBV感染と肝発癌の検討

荒川恭宏, 加藤幸一郎, 新家卓郎, 今井則博, 阿知波宏一, 山田恵一, 石津洋二, 葛谷貞二, 本多隆, 林和彦, 石上雅敏, 後藤秀実

肝臓 Vol. 55 ( Suppl.2 ) page： A599 - A599 2014.9

The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma

KUZUYA Teiji, ISHIGAMI Masatoshi, NIINOMI Takurou, IMAI Norihiro, ACHIWA Kouichi, ARAKAWA Takahiro, YAMADA Keiichi, NAKANO Satoshi, ISHIZU Yoji, HONDA Takashi, HAYASHI Kazuhiko, ISHIKAWA Tetsuya, NAKANO Isao, KATANO Yoshiaki, ITOH Akihiro, HIROOKA Yoshiki, GOTO Hidemi

Kanzo Vol. 54 ( 7 ) page： 505 - 506 2013.5

Publishing type：Research paper (scientific journal) Publisher：The Japan Society of Hepatology

We investigated the relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma (HCC). Subjects were 64 patients who began sorafenib therapy. Contrast enhanced CT images were taken at baseline and after 2 weeks of sorafenib treatment. In patients with fever, the ratio of patients demonstrating the disappearance or decrease of lesion contrast on contrast enhanced CT images was significantly higher than in those without fever (91.3% and 61.0%, respectively, p=0.010, Fisher's exact probability test). The results suggested the relationship between the fever and contrast change on contrast enhanced CT.

DOI： 10.2957/kanzo.54.505

Scopus

researchmap

Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.

Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Gut and liver Vol. 7 ( 2 ) page： 246 - 51 2013.3

Clinical trial of percutaneous radio frequency ablation therapy by two-step insertion method using VirtuTRAXTM instrument navigator

Kuzuya Teiji, Hayashi Kazuhiko, Ishigami Masatoshi, Ishikawa Tetsuya, Nakano Isao, Katano Yoshiaki, Itoh Akihiro, Hirooka Yoshiki, Izumi Namiki, Goto Hidemi, Ishizu Yoji, Niinomi Takurou, Imai Norihiro, Achiwa Kouichi, Arakawa Takahiro, Yamada Keiichi, Nakano Satoshi, Honda Takashi

Kanzo Vol. 54 ( 12 ) page： 850 - 853 2013

Publishing type：Research paper (scientific journal) Publisher：The Japan Society of Hepatology

We performed percutaneous radio frequency ablation (RFA) therapy by two-step insertion method using VirtuTRAXTM (GE Healthcare, USA) instrument navigator. Subjects were 16 patients (23 nodules) with hepatocellular carcinoma. VirtuTRAXTM position sensor was attached to the hilt of 14-gauge outer needle. In all cases, we could perform 17- gauge Cool-tip RFA without the positional gap between the virtual tract and the actual needle which was caused by the deflection of the needle. The reasons without causing the positional gap were that the outer needle was more rigid than Cool-tip needle, and that it was inserted using initial insertion of a 21-gauge guided needle. RFA by two-step insertion method using VirtuTRAXTM is suggested to be more safe and effective than conventional RFA.

DOI： 10.2957/kanzo.54.850

Scopus

researchmap

An Increase in Lesion Density can Predict Lower Local Recurrence after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

Imai Norihiro, Katano Yoshiaki, Kuzuya Teiji, Honda Takashi, Hayashi Kazuhiko, Ishigami Masatoshi, Itoh Akihiro, Hirooka Yoshiki, Goto Hidemi

HEPATO-GASTROENTEROLOGY Vol. 60 ( 125 ) page： 965 - 970 2013

Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load

ARASE Yasuji, SUZUKI Yoshiyuki, SUZUKI Fumitaka, AKUTA Norio, SEZAKI Hitomi, KAWAMURA Yusuke, KOBAYASHI Masahiro, IMAI Norihiro, SEKO Yuya, HOSAKA Tetsuya, MATSUMOTO Naoki, SAITO Satoshi, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

Hepatology research : the official journal of the Japan Society of Hepatology Vol. 42 ( 8 ) page： 750 - 756 2012.8

Combination therapy with transcatheter arterial infusion chemotherapy using miriplatin and percutaneous radiofrequency ablation for hepatocellular carcinoma

IMAI Norihiro, IKEDA Kenji, SEKO Yuya, HARA Tasuku, OHNO Atsushi, MATSUMOTO Naoki, KAWAMURA Yusuke, HOSAKA Tetsuya, KOBAYASHI Masahiro, SAITOH Satoshi, SEZAKI Hitomi, AKUTA Norio, SUZUKI Fumitaka, SUZUKI Yoshiyuki, ARASE Yasuji, KUMADA Hiromitsu

Kanzo Vol. 53 ( 6 ) page： 351-354 - 354 2012.6

Language：English Publishing type：Research paper (scientific journal) Publisher：The Japan Society of Hepatology

Miriplatin is a platinum complex developed to treat hepatocellular carcinoma (HCC) via administration into the hepatic artery as a sustained-release suspension in iodized oil. We retrospectively evaluated the efficacy of combination therapy with transcatheter arterial infusion chemotherapy using miriplatin and percutaneous radiofrequency ablation for HCC in 11 patients. Immediately after transcatheter arterial infusion chemotherapy using miriplatin, we performed radiofrequency ablation. The greatest long-axis and short-axis dimensions of the area coagulated after combination therapy were 42 mm (35-80 mm) and 34 mm (32-60 mm), respectively. During follow-up (median 12 months), there was no recurrence from the same subsegment. No serious adverse events were observed. These results suggested that using the combination therapy, it is possible to finish one treatment session for patient with HCC.

DOI： 10.2957/kanzo.53.351

researchmap

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL

Matsumoto, N; Arase, Y; Seko, Y; Imai, N; Kawamura, Y; Sezaki, H; Hosaka, T; Akuta, N; Kobayashi, M; Kobayashi, M; Suzuki, Y; Saito, S; Suzuki, F; Ikeda, K; Kumada, H; Aida, K; Kobayashi, T

HEPATOLOGY RESEARCH Vol. 42 ( 6 ) page： 558 - 563 2012.6

Language：English Publishing type：Research paper (scientific journal) Publisher：Hepatology Research

Aim: The aim of this study was to evaluate the prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhotic patients with fasting plasma glucose (FPG) level of <126mg/dL. Methods: A total of 263 patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) positive liver cirrhosis, FPG level of <126mg/dL, and had diabetes status evaluated by the use of 75-g oral glucose tolerance test (OGTT), were enrolled in this study. Plasma glucose and insulin levels were analyzed periodically for 3h after oral glucose loading. Diabetes was defined as a 2-h post-load glucose on the OGTT of ≥200mg/dL. The prevalence of diabetes by use of OGTT and predictive factors for diabetes were evaluated by the use of the Mann-Whitney U-test, Fisher's exact probability test or multivariate analysis by logistic regression. Hypoalbuminemia was defined as serum albumin level of <3.9g/dL. Elevated indocyanine green retention rate at 15min (ICG R15) was regarded as ≥ 25%. Results: Out of 263 patients, 44 (16.7%) were diagnosed as having diabetes. Multivariate analysis showed that diabetes occurred when patients had hypoalbuminemia of <3.9g/dL (odds ratio [OR] 2.33; 95% confidential interval [CI]=1.04-5.24; P=0.040) and ICG R15 of <25% (OR 2.36; 95%CI=1.01-5.58). Conclusions: Hypoalbuminemia and elevated ICG R15 in hepatitis virus related cirrhotic patients with FPG level of <126mg/day enhance diabetes pattern after OGTT with significant difference. © 2012 The Japan Society of Hepatology.

DOI： 10.1111/j.1872-034X.2011.00957.x

Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderlv patients

ARASE Yasuji, KOBAYASHI Mariko, SUZUKI Fumitaka, SUZUKI Yoshiyuki, KAWAMURA Yusuke, AKUTA Norio, IMAI Norihiro, KOBAYASHI Masahiro, SEZAKI Hitomi, MATSUMOTO Naoki, SAITO Satoshi, HOSAKA Tetsuya, IKEDA Kenji, KUMADA Hiromitsu, OHMOTO Yuki, AMAKAWA Kazuhisa, HSIEH Shiun Dong, OGAWA Kyoko, TANABE Maho, TSUJI Hiroshi, KOBAYASHI Tetsuro

Hepatology research : the official journal of the Japan Society of Hepatology Vol. 42 ( 3 ) page： 264 - 272 2012.3

Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H

Japanese journal of clinical oncology Vol. 42 ( 3 ) page： 175 - 82 2012.3

Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.

Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, Imai N, Kobayashi M, Sezaki H, Matsumoto N, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Hsieh SD, Ogawa K, Tanabe M, Tsuji H, Kobayashi T

Hepatology research : the official journal of the Japan Society of Hepatology Vol. 42 ( 3 ) page： 264 - 272 2012.3

Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.

Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H

The American journal of gastroenterology Vol. 107 ( 2 ) page： 253 - 61 2012.2

Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure

IMAI Norihiro, IKEDA Kenji, SEKO Yuya, MATSUMOTO Naoki, KAWAMURA Yusuke, HOSAKA Tetsuya, KOBAYASHI Masahiro, SAITOH Satoshi, SEZAKI Hitomi, AKUTA Norio, SUZUKI Fumitaka, SUZUKI Yoshiyuki, ARASE Yasuji, KUMADA Hiromitsu

Nippon Shokakibyo Gakkai Zasshi Vol. 108 ( 11 ) page： 1872-1878 - 1878 2011.11

Language：English Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Gastroenterology

Miriplatin is a novel lipophilic platinum complex developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting chronic renal failure, there is no reliable data regarding clinical toxicity of miriplatin in HCC patients with chronic renal failure. We retrospectively evaluated the safety and efficacy of transcatheter arterial chemotherapy with miriplatin in 67 HCC patients with chronic renal failure (estimated glomerular filtration rate [GFR] by the Cockcroft-Gault equation <60ml/min). Estimated GFR within 2 months after miriplatin administration did not decrease significantly by the Wilcoxon signed rank test (pretreatment;46ml/min, 1 month;48ml/min;P=0.019, 2 months;45ml/min;P=0.619 [P<0.003 was significant by the Bonferroni correction]). Complete response in terms of tumor necrosis was achieved in 14 of 67 patients and no serious adverse events were observed. These results suggested that transcatheter arterial chemotherapy with miriplatin can be used safely for HCC patients with chronic renal failure.

DOI： 10.11405/nisshoshi.108.1872

researchmap

Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure

Imai N.

Journal of Japanese Society of Gastroenterology Vol. 108 ( 11 ) page： 1872-1878 2011.11

Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy

ARASE Yasuji, SUZUKI Fumitaka, KAWAMURA Yusuke, SUZUKI Yoshiyuki, KOBAYASHI Masahiro, MATSUMOTO Naoki, AKUTA Norio, SEZAKI Hitomi, HOSAKA Tetsuya, OGAWA Kyoko, IMAI Norihiro, SEKO Yuya, SAITO Satoshi, IKEDA Kenji, KOBAYASHI Mariko, KUMADA Hiromitsu

Hepatology research : the official journal of the Japan Society of Hepatology Vol. 41 ( 10 ) page： 946 - 954 2011.10

　 PREV - NEXT 　

<IMAI Norihiro>

Papers - IMAI Norihiro